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TEMPORAL TRENDS IN CARDIOGENIC SHOCK COMPLICATING ACUTE 
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BSTRACT
 
Background
 
Limited information is available on
trends in the incidence of and mortality due to car-
diogenic shock complicating acute myocardial infarc-
tion. We studied the incidence of cardiogenic shock
complicating acute myocardial infarction and in-hos-
pital death rates among patients with this condition
in a single community from 1975 through 1997.
 
Methods
 
We conducted an observational study of
9076 residents of metropolitan Worcester, Massachu-
setts, who were hospitalized with confirmed acute
myocardial infarction in all local hospitals during 11
one-year periods between 1975 and 1997. Our study
included periods before and after the advent of re-
perfusion therapy.
 
Results
 
The incidence of cardiogenic shock re-
mained relatively stable over time, averaging 7.1 per-
cent among patients with acute myocardial infarction.
The results of a multivariable regression analysis in-
dicated that the patients hospitalized during recent
study years were not at a substantially lower risk for
shock than patients hospitalized in the mid-to-late
1970s. Patients in whom cardiogenic shock devel-
oped had a significantly greater risk of dying during
hospitalization (71.7 percent) than those who did not
have cardiogenic shock (12.0 percent, P<0.001). A
significant trend toward an increase in in-hospital
survival among patients with cardiogenic shock in the
mid-to-late 1990s was found in crude and adjusted
analyses.
 
Conclusions
 
Our findings indicate no significant
change in the incidence of cardiogenic shock com-
plicating acute myocardial infarction over a 23-year
period. However, the short-term survival rate has
increased in recent years at the same time as the
use of coronary reperfusion strategies has increased.
(N Engl J Med 1999;340:1162-8.)
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ESPITE recent advances in the care of
patients with acute coronary disease and
the benefits associated with the early use of
reperfusion strategies, cardiogenic shock
as a complication of acute myocardial infarction con-
tinues to be associated with a dismal prognosis.
 
1,2
 
With improvements in electrocardiographic moni-
toring and the treatment of life-threatening ventric-
ular arrhythmias, cardiogenic shock has emerged as
the most common cause of death among patients
admitted to the hospital with acute myocardial infarc-
tion.
 
3
 
 The incidence of cardiogenic shock complicat-
ing acute myocardial infarction ranges from 5 to 15
percent.
 
1,4-10 
 
Population-based estimates of changes
D
 
over time in the incidence of cardiogenic shock re-
main limited
 
11
 
; the majority of data about either the
incidence of cardiogenic shock or the prognosis as-
sociated with this complication have been derived
from single hospitals and specialty referral centers or
in the context of post hoc analyses of randomized
trials. Because there is no definitive treatment to re-
establish blood flow in the infarct-related coronary
artery, the in-hospital death rate associated with car-
diogenic shock exceeds 65 percent
 
4,10,12-15
 
; from the
mid-1970s through the late 1980s, there was little
change in the mortality rate associated with this clin-
ical syndrome.
 
11
 
A growing trend has been to use more aggressive
therapeutic interventions early in patients who have
cardiogenic shock as a result of acute myocardial in-
farction.
 
16
 
 In the current era of research on cost effec-
tiveness and outcomes and of aggressive efforts to
limit infarct size and maintain left ventricular func-
tion, it remains important to study trends in the in-
cidence of cardiogenic shock complicating acute my-
ocardial infarction and in case fatality rates and to
study the possible effect of new treatment strategies.
We undertook a communitywide study in order to
extend the findings of a report on temporal trends
(for the period from 1975 through 1988) in the in-
cidence of cardiogenic shock and in-hospital death
rates among patients with confirmed acute myocar-
dial infarction who had been admitted to all hospi-
tals in metropolitan Worcester, Massachusetts.
 
11
 
 The
earlier study predated the use of thrombolytic agents
and the increasing use of myocardial-revascularization
approaches in patients with acute coronary disease.
The current findings are based on data on 9076 res-
idents of the Worcester metropolitan area who had
acute myocardial infarction and were admitted to hos-
pitals in greater Worcester from 1975 through 1997.
 
METHODS
 
Study Population
 
The study population consisted of residents of metropolitan
Worcester who were assigned a diagnosis of acute myocardial in-
farction at discharge from 1 of the 16 teaching and community
hospitals (the number of hospitals became smaller during the
Copyright © 1999 Massachusetts Medical Society. All rights reserved. 
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course of the study as a result of hospital mergers and consolida-
tions) in the standard metropolitan statistical area (1990 popula-
tion, 437,000) during 1975, 1978, 1981, 1984, 1986, 1988, 1990,
1991, 1993, 1995, and 1997.
 
17-19
 
 The medical records of all po-
tentially eligible patients were reviewed and the diagnosis was con-
firmed according to preestablished criteria.
 
17-19
 
Cardiogenic shock was defined as a systolic blood pressure of
less than 80 mm Hg in the absence of hypovolemia and associated
with cyanosis, cold extremities, changes in mental status, persist-
ent oliguria, or congestive heart failure.
 
11
 
 The definition of car-
diogenic shock remained the same in all periods studied; the dis-
order was defined in the study so that patients with classic signs
and symptoms of this clinical syndrome would be included.
 
Data Collection
 
From the hospital records of patients with validated acute my-
ocardial infarction, we abstracted demographic, medical-history,
and clinical data as well as information about the use of therapeu-
tic interventions and specialized procedures.
 
17-21
 
 Data regarding
the use of thrombolytic agents, coronary-artery bypass grafting,
and percutaneous transluminal coronary angioplasty were includ-
ed as these therapies became available in clinical practice.
 
Statistical Analysis
 
Differences in the distribution of characteristics between patients
with cardiogenic shock and those without, and between patients
with shock who survived to be discharged from the hospital and
those who did not, were studied with the use of chi-square tests
for categorical variables and t-tests for continuous variables, as ap-
propriate. All tests of statistical significance were two-tailed. Mul-
tivariable logistic-regression models were used to assess the sig-
nificance of temporal trends in the incidence of cardiogenic shock
while controlling for potentially confounding demographic, med-
ical-history, and clinical factors. Control variables included indica-
tors for the following: age, male sex, history of various coexisting
disorders (angina, diabetes, hypertension, or stroke), and type of
acute myocardial infarction (initial vs. recurrent, Q-wave vs. non–
Q-wave, and anterior vs. inferior or posterior).
Because of the observational, nonrandomized nature of this
study, and because of our methods of data collection, which did
not allow us to determine whether a medical therapy or surgical
intervention preceded or came after the occurrence of cardiogen-
ic shock, we did not control for the use of various interventional
procedures (cardiac catheterization, coronary-artery bypass graft-
ing, or percutaneous transluminal coronary angioplasty) or med-
ical therapies (such as thrombolytic agents). Another reason that
we did not control for these practices is the difficulty of interpret-
ing any observed adjusted estimates of association. Our approach
to model building focused on the hypothesis that variations in
the incidence of cardiogenic shock over time were the result of
changes in the demographic or clinical characteristics (or both)
of the study sample. We recognize that these trends might also
reflect improvements in the use of various approaches to care —
and increasing use of these approaches — over time.
We studied the effect of cardiogenic shock on in-hospital death
rates by calculating in-hospital case fatality rates. Multivariable lo-
gistic-regression analyses were carried out to assess the effect of
cardiogenic shock on mortality during hospitalization and to
study changes over time in the in-hospital case fatality rates asso-
ciated with cardiogenic shock while controlling for potentially
confounding factors. This approach to model development was
similar to that described for the end point of cardiogenic shock.
 
RESULTS
 
Base-Line Characteristics
 
During all the study years combined, the patients
with cardiogenic shock were significantly older than
those who did not have this complication (Table 1).
A significantly greater proportion of the patients who
had cardiogenic shock were women, had a history of
diabetes or stroke, and had acute myocardial infarc-
tion that was recurrent, Q-wave in type, and anterior
in location. Patients with cardiogenic shock were sig-
nificantly more likely to undergo coronary-artery by-
pass grafting, intraaortic balloon counterpulsation,
and percutaneous transluminal coronary angioplasty
than those without shock. From the mid-1980s un-
til the late 1990s, thrombolytic therapy was used in
slightly less than one quarter of patients, irrespective
of the presence or absence of cardiogenic shock.
Table 2 summarizes changes in the characteristics
of patients in whom cardiogenic shock developed or
did not develop over the 23-year period under study.
The characteristics are categorized in five periods
combining two years each and one single-year period
to make analyses of the data easier to interpret and
to coincide with changes in the care of patients with
acute myocardial infarction. Over time, patients with
acute myocardial infarction were increasingly older,
more likely to have selected coexisting conditions,
and more likely to have a non–Q-wave myocardial
infarction. The use of thrombolytic therapy, cardiac
catheterization, percutaneous transluminal coronary
angioplasty, and coronary-artery bypass grafting in-
creased over time among all patients; the use of my-
ocardial-revascularization techniques increased mark-
edly during the mid-to-late 1990s. An increasing
proportion of the patients with cardiogenic shock
presented with an initial acute myocardial infarction
over time. Over the 23-year study period, the use of
intraaortic balloon counterpulsation increased dra-
matically among patients with cardiogenic shock.
 
*Data were available only for the period from 1986 to 1997.
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C
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S
 
HOCK
 
P
 
RESENT
 
(N=644)
S
 
HOCK
 
A
 
BSENT
 
(N=8432)
P
V
 
ALUE
 
Mean age (yr) 71.6 67.7 <0.001
Male sex (%) 50.8 60.3 <0.001
Coexisting conditions (%)
Angina
Diabetes
Hypertension
Stroke
27.5
28.9
51.2
12.1
26.9
25.4
51.5
8.4
0.76
<0.05
0.91
<0.001
Type of myocardial infarction (%)
Initial
Q-wave
Anterior
60.2
68.1
52.6
65.7
49.1
44.8
<0.005
<0.001
<0.001
Procedures (%)
Cardiac catheterization
Coronary-artery bypass surgery*
Intraaortic balloon counterpulsation
Percutaneous transluminal coronary
angioplasty*
23.1
7.4
20.0
16.1
20.2
3.1
1.5
7.9
0.08
<0.001
<0.001
<0.001
Use of thrombolytic agents (%)* 22.8 21.6 0.59
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Incidence of Cardiogenic Shock
 
The incidence of cardiogenic shock remained rel-
atively stable over the initial decade of this study; in-
cidence peaked in 1988, after which there was an in-
consistent decline in the proportion of patients with
shock. The overall incidence of cardiogenic shock
averaged 7.1 percent over the 23-year study period
(Fig. 1).
We carried out two regression analyses to study
changes over time in the incidence of cardiogenic
shock while adjusting for various potentially con-
founding factors (Table 3). After controlling for age,
sex, and history of cardiovascular disease, we found
nonsignificant trends in the multivariable-adjusted risk
of shock over the period under study — results sim-
ilar to the unadjusted findings (Table 3). After con-
trolling for age, sex, medical history, and character-
istics of acute myocardial infarction, we found that
the risk of cardiogenic shock also did not change
significantly over time.
 
In-Hospital Case Fatality Rates
 
Patients with acute myocardial infarction in whom
cardiogenic shock developed had significantly higher
in-hospital case fatality rates overall (71.7 percent, vs.
12.0 percent among those without shock; P<0.001)
and during each of the periods under study (Fig. 2).
The in-hospital death rates among the patients with
cardiogenic shock remained relatively constant until
the mid-to-late 1990s, averaging approximately 77
percent; 61 percent of patients with cardiogenic shock
died in 1993 and 1995 and 59 percent in 1997.
A logistic-regression analysis was carried out to
control simultaneously for age, sex, medical history,
and characteristics of acute myocardial infarction in
determining the association between the occurrence
of cardiogenic shock and in-hospital mortality. This
analysis confirmed the markedly higher risk of in-
hospital death among patients who had cardiogenic
shock, as compared with those who did not (adjusted
odds of dying, 21.0; 95 percent confidence interval,
17.2 to 25.6) for the combined study periods. A
 
*MI denotes myocardial infarction, CABG coronary-artery bypass grafting, IBCP intraaortic balloon counterpulsation, and PTCA percutaneous trans-
luminal coronary angioplasty.
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AND
 
 1984 1986 
 
AND
 
 1988 1990 
 
AND
 
 1991 1993 
 
AND
 
 1995 1997
P V
 
ALUE
 
 
 
FOR
 
 T
 
REND
 
SHOCK
 
 
 
PRESENT
 
(
 
N
 
=117)
 
SHOCK
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(
 
N
 
=936)
 
SHOCK
 
 
 
PRESENT
SHOCK
ABSENT
 
Mean age (yr) 70 65 70 67 74 67 74 69 72 69 71 70 <0.06 <0.001
Male sex (%) 48 63 59 62 47 61 51 57 48 59 52 58 0.78 <0.001
Coexisting con-
ditions (%)
Angina
Diabetes
Hypertension
Stroke
21
29
44
9
25
22
41
5
29
25
40
11
29
22
51
8
31
25
44
13
26
25
49
8
33
25
58
17
27
26
53
9
25
40
65
11
28
27
57
10
28
27
62
14
25
33
60
11
0.56
0.23
<0.001
0.30
0.77
<0.001
<0.001
<0.001
Type of MI (%)
Initial
Q wave
Anterior
57
85
52
67
67
51
55
81
56
65
58
52
61
64
57
69
51
49
52
58
56
67
46
42
66
55
48
62
36
35
73
63
46
64
32
37
<0.025
<0.001
0.29
<0.05
<0.001
<0.001
Procedures (%)
Cardiac cathe-
terization
CABG
IBCP
PTCA
5
—
5
—
2
—
0
—
7
—
5
—
7
1
1
—
12
3
13
2
25
2
2
3
25
3
16
7
21
2
2
4
49
10
46
29
35
4
2
12
52
14
42
28
39
5
3
14
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
Use of throm-
bolytic
agents (%)
— — — — 8 15 26 25 33 25 25 20 <0.001 <0.001
 
Figure 1.
 
 Temporal Trends in the Incidence of Cardiogenic
Shock in Patients with Acute Myocardial Infarction.
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similar adverse effect of cardiogenic shock on in-
hospital death rates was found when this analysis was
restricted to patients in whom shock developed over
the period of increasing use of myocardial-reperfusion
strategies (1986 through 1997).
As in the analysis of trends over time in the in-
cidence of cardiogenic shock, we performed two
separate multivariable regression analyses to evaluate
changes over time in in-hospital mortality of pa-
tients with cardiogenic shock while controlling for
previously described prognostic characteristics. The
results suggested considerable improvements in the
in-hospital survival of patients with shock, particu-
larly during the 1990s (Table 4). Depending on the
covariates adjusted for, the risk of dying from car-
diogenic shock was markedly lower in the mid-to-
late 1990s than in the two previous decades.
The patients with cardiogenic shock who survived
to discharge were significantly younger than those
who did not survive (Table 5). The patients who sur-
vived were significantly more likely to have received
angiotensin-converting–enzyme inhibitors, antiplate-
let agents, beta-blockers, digoxin, and thrombolytic
agents. Patients who died from this complication were
less likely to have undergone coronary-artery bypass
grafting, percutaneous transluminal coronary angio-
plasty, or intraaortic balloon counterpulsation.
 
DISCUSSION
 
The results of this population-based study suggest
a relatively constant incidence of cardiogenic shock
over the 23-year period under study; a significantly
higher in-hospital death rate among patients in whom
shock developed; and improvement over time in the
in-hospital survival rate of patients with cardiogenic
shock, particularly during the mid-to-late 1990s.
The incidence of cardiogenic shock after acute
myocardial infarction ranges from 5 to 15 percent in
published studies.
 
1,4-11
 
 This relatively wide range re-
flects, in part, the varying definitions of acute myo-
cardial infarction and cardiogenic shock, the use of
representative as opposed to more highly selected pa-
tient samples, and the rates of use of therapeutic
options that may reduce the risk of cardiogenic shock.
The overall incidence of cardiogenic shock in the
current study falls within this range. In the world-
wide Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-1) randomized trial, cardiogenic
shock developed in 7.2 percent of approximately
41,000 patients with acute myocardial infarction.
 
22
 
*The odds ratio was adjusted initially for age, sex, and medical history. The second adjustment was
for age, sex, medical history, and the order (initial vs. recurrent), type, and location of the acute my-
ocardial infarction. 
†This was the reference category.
 
T
 
ABLE 3. TEMPORAL TRENDS IN THE CRUDE AND MULTIVARIABLE-ADJUSTED ODDS
OF CARDIOGENIC SHOCK IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION.
STUDY PERIOD AND YEARS
PERCENTAGE
OF PATIENTS
WITH SHOCK
WITHOUT
ADJUSTMENT FIRST ADJUSTMENT SECOND ADJUSTMENT
odds ratio (95% confidence interval)*
Mid-to-late 1970s 
(1975 and 1978)†
7.2 1.0 1.0 1.0
Early 1980s 
(1981 and 1984)
7.2 1.00 (0.77–1.30) 0.95 (0.73–1.23) 0.99 (0.75–1.31)
Mid-to-late 1980s 
(1986 and 1988)
8.3 1.17 (0.89–1.52) 1.10 (0.84–1.43) 1.23 (0.92–1.63)
Early 1990s 
(1990 and 1991)
5.9 0.81 (0.61–1.07) 0.73 (0.55–0.98) 0.94 (0.70–1.26)
Mid-1990s 
(1993 and 1995)
7.0 0.97 (0.75–1.27) 0.89 (0.68–1.15) 1.27 (0.96–1.68)
Late 1990s (1997) 7.1 0.98 (0.72–1.33) 0.87 (0.64–1.18) 1.31 (0.95–1.80)
Figure 2. Temporal Trends in In-Hospital Death Rates among
Patients with Acute Myocardial Infarction According to the
Presence or Absence of Cardiogenic Shock.
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In GUSTO-1, patients treated with accelerated re-
combinant tissue plasminogen activator were signif-
icantly less likely to have shock; this finding suggests
the possible benefit of early reperfusion that is asso-
ciated with the use of this thrombolytic regimen.22
We have previously documented progressive de-
clines since the mid-1970s in the in-hospital death
rates of patients with acute myocardial infarction.17-19,23
We have also found declines in the rates of out-of-
hospital death attributed to coronary heart disease.24
Therefore, it is possible that the patients who make
it to the hospital and in whom cardiogenic shock
subsequently develops are sicker, and thus at greater
risk, than those who do not; this explains in part
some of the nonsignificant changes in the incidence
of cardiogenic shock that were found. Because of the
nonrandomized nature of the current study, we could
not address directly the association between the in-
creased use of thrombolytic agents and surgical in-
terventions and the risk of shock.
Patients should be encouraged to seek medical care
as soon as possible after having symptoms of acute
myocardial infarction, because immediate care may
reduce the incidence of cardiogenic shock and the
associated mortality. Efforts to decrease the inci-
dence of cardiogenic shock should focus on identify-
ing patients who are at high risk for this complica-
tion and instructing them to seek care immediately
after the onset of acute coronary symptoms so that
appropriate monitoring, risk stratification, and inter-
vention can be undertaken.25 Aggressive interven-
tion may result in improved survival rates among pa-
tients in whom cardiogenic shock has developed,
because the early detection of precursors of shock or
signs of circulatory failure are likely to result in in-
creased and timely intervention.
Patients in whom cardiogenic shock has developed
*The odds ratio was adjusted initially for age, sex, and medical history. The second adjustment was
for age, sex, medical history, and the order (initial vs. recurrent), type, and location of the acute my-
ocardial infarction. 
†This was the reference category.
TABLE 4. TEMPORAL TRENDS IN THE CRUDE AND MULTIVARIABLE-ADJUSTED ODDS
OF IN-HOSPITAL DEATH AMONG PATIENTS WITH CARDIOGENIC SHOCK COMPLICATING 
ACUTE MYOCARDIAL INFARCTION.
STUDY PERIOD
WITHOUT 
ADJUSTMENT FIRST ADJUSTMENT SECOND ADJUSTMENT
odds ratio (95% confidence interval)*
Mid-to-late 1970s (1975 and 1978)† 1.0 1.0 1.0
Early 1980s (1981 and 1984) 1.02 (0.56–1.85) 0.97 (0.52–1.81) 1.05 (0.54–2.02)
Mid-to-late 1980s (1986 and 1988) 1.30 (0.70–2.42) 1.00 (0.52–1.92) 1.17 (0.57–2.39)
Early 1990s (1990 and 1991) 0.85 (0.45–1.60) 0.69 (0.35–1.34) 0.70 (0.35–1.41)
Mid-1990s (1993 and 1995) 0.49 (0.28–0.86) 0.41 (0.23–0.73) 0.43 (0.23–0.80)
Late 1990s (1997) 0.46 (0.24–0.86) 0.39 (0.20–0.76) 0.41 (0.20–0.83)
*Data were available only for the period from 1990 to 1995.
†Data were available only for the period from 1986 to 1995.
TABLE 5. CHARACTERISTICS OF PATIENTS WITH CARDIOGENIC 
SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION
ACCORDING TO WHETHER THEY SURVIVED TO DISCHARGE 
OR DIED IN THE HOSPITAL.
CHARACTERISTIC
SURVIVED
(N=182)
DIED
(N=462)
P
VALUE
Mean age (yr) 66.2 73.7 <0.001
Age (%)
<55 yr
55–64 yr
65–74 yr
»75 yr
18.1
24.7
30.8
26.4
4.1
16.2
28.8
50.9
<0.001
Male sex (%) 51.7 50.4 0.78
Coexisting conditions (%)
Angina
Diabetes
Hypertension
Stroke
24.2
28.0
51.7
9.9
28.8
29.2
51.1
13.0
0.24
0.76
0.90
0.28
Myocardial infarction (%)
Initial
Q wave
Anterior
63.2
66.9
49.1
59.0
68.6
54.0
0.33
0.68
0.28
Medications
Angiotensin-converting–enzyme 
inhibitors*
Antiplatelet agents
Beta-blockers
Calcium-channel blockers†
Digoxin
Thrombolytic agents†
76.5
55.5
51.1
41.6
62.1
33.6
31.5
37.0
33.1
44.1
48.7
17.9
<0.001
<0.001
<0.001
0.64
<0.005
<0.001
Procedures
Coronary-artery bypass surgery†
Intraaortic balloon counterpulsation
Percutaneous transluminal coronary
angioplasty
14.4
33.5
32.0
4.3
14.7
9.0
<0.001
<0.001
<0.001
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continue to have a markedly higher risk of dying in
the hospital than do patients without cardiogenic
shock. However, the prognosis for patients with car-
diogenic shock who are in the hospital has improved
considerably in recent years. This improvement may
be due to the increasingly aggressive strategies of in-
tervention used or to changes in the natural history
of shock, with fewer cases that subsequently result
in death identified early in the course of the illness.
In our unadjusted analyses, patients who survived
cardiogenic shock were significantly more likely than
those who died from it to have received beneficial
therapies for cardiac disease, and they were more
likely to have received aggressive treatment for acute
coronary disease through interventional approaches.
The findings suggest that these therapies have a ben-
eficial effect on the survival of patients with acute
myocardial infarction in whom cardiogenic shock
has developed.
The use of intraaortic balloon counterpulsation in
patients with cardiogenic shock has been shown to
result in initially favorable clinical and hemodynamic
responses; however, in the majority of studies in which
this intervention was used, death was merely de-
layed.26,27 A number of nonrandomized studies sug-
gest that percutaneous transluminal coronary angio-
plasty improves short-term survival among patients
with cardiogenic shock, with survival contingent on
the successful establishment of coronary reperfu-
sion.14,15,28,29 Uncontrolled studies of bypass grafting
show that this therapy improves short-term survival
among patients with cardiogenic shock when they
are treated soon after shock has developed.30,31
Although thrombolytic therapy has consistently
been shown to decrease mortality after acute myo-
cardial infarction,32,33 no large, randomized, controlled
trial has found that the use of clot-lysing therapy
reduces the incidence of cardiogenic shock or im-
proves survival after cardiogenic shock has devel-
oped. In GUSTO-1, 56 percent of all patients with
cardiogenic shock died in the hospital, regardless of
the thrombolytic regimen used.22 Nonetheless, it
has been hypothesized that the early resumption of
coronary blood flow in the infarct-affected artery by
means of thrombolytic agents, percutaneous translu-
minal coronary angioplasty or coronary-artery by-
pass grafting supported by intraaortic balloon coun-
terpulsation, or both, reduces the size of the infarct,
decreases the risk of ongoing myocardial ischemia
and left ventricular dysfunction, and improves sur-
vival among patients with cardiogenic shock.12,28 Re-
cent analyses from the GUSTO-1 trial suggest that
the use of a more aggressive revascularization strat-
egy in patients with cardiogenic shock, after initial
treatment with a thrombolytic regimen, is associated
with a reduction in short-term mortality even after
control for differences that affected the selection of
treatment.34,35
The current study was carried out in a well-defined
metropolitan area whose sociodemographic and eco-
nomic characteristics reflect those of the U.S. popu-
lation with the exception of race (the vast majority
of the residents of metropolitan Worcester are white).
The strengths of this study are its large sample; its
population-based design, which enhances the gener-
alizability of the findings; and the inclusion of all
hospitals in the area. The study has several limitations,
however. Specific therapies for patients with cardio-
genic shock were not determined by a standardized
study protocol but, rather, by the many individual
physicians practicing at the hospitals. In addition,
because of the methods of data collection and the re-
cording of data from hospitals, it was difficult to de-
termine whether a particular drug or procedure was
used before or after cardiogenic shock developed;
therefore, we did not control for the use of these
therapies in additional multivariable-adjusted regres-
sion analyses. Finally, in analyzing the declining mor-
tality associated with cardiogenic shock over time,
one must be careful in interpreting the multivariable-
adjusted odds of dying, because they may overesti-
mate the actual risk ratio calculated in cohort studies.36
The rate of use of thrombolytic agents and inter-
ventional procedures was lower in our community-
wide observational study than in other studies that
have focused specifically on the use of targeted in-
terventions in patients with cardiogenic shock.12,28,31
Most patients failed to receive clot-lysing therapy
because of prolonged delays in seeking medical care.
An extended prehospital delay may be associated
with more extensive myocardial necrosis and a great-
er risk of shock. Patients with cardiogenic shock may
also be more likely to be excluded from clinical trials
of new approaches to treating acute myocardial in-
farction that are ultimately found to be beneficial.37 
As evidenced by the results of this study, cardio-
genic shock continues to develop at a relatively high
rate after acute myocardial infarction, even though
thrombolytic agents and interventional procedures are
being used more. The in-hospital death rate among
patients with this complication remains high. Until
the results of a multicenter, randomized trial that
has been designed to study the effect of aggressive
interventional approaches on the incidence and prog-
nosis of cardiogenic shock in association with acute
myocardial infarction are published,12,38 it remains im-
portant to study trends in incidence and prognosis.
This is particularly crucial if the use of surgical inter-
ventions and myocardial-reperfusion strategies con-
tinues to increase.
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